Data Insights

DN-1508052 by Shanghai De Novo Pharmatech for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval

DN-1508052 is under clinical development by Shanghai De Novo Pharmatech and currently in Phase I for Recurrent Head And Neck...

Likelihood of Approval and Phase Transition Success Rate Model - DN-1508052 in Recurrent Head And Neck Squamous Cell Carcinoma

Data Insights

DN-1508052 by Shanghai De Novo Pharmatech for Oral Cavity (Mouth) Cancer: Likelihood of Approval

DN-1508052 is under clinical development by Shanghai De Novo Pharmatech and currently in Phase I for Oral Cavity (Mouth) Cancer....

Likelihood of Approval and Phase Transition Success Rate Model - DN-1508052 in Oral Cavity (Mouth) Cancer

Data Insights

DN-1508052 by Shanghai De Novo Pharmatech for Oropharyngeal Cancer: Likelihood of Approval

DN-1508052 is under clinical development by Shanghai De Novo Pharmatech and currently in Phase I for Oropharyngeal Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - DN-1508052 in Oropharyngeal Cancer

Data Insights

DN-1508052 by Shanghai De Novo Pharmatech for Laryngeal Cancer: Likelihood of Approval

DN-1508052 is under clinical development by Shanghai De Novo Pharmatech and currently in Phase I for Laryngeal Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - DN-1508052 in Laryngeal Cancer

Data Insights

DN-1508052 by Shanghai De Novo Pharmatech for Hypopharyngeal Cancer: Likelihood of Approval

DN-1508052 is under clinical development by Shanghai De Novo Pharmatech and currently in Phase I for Hypopharyngeal Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - DN-1508052 in Hypopharyngeal Cancer

Data Insights

DN-1508052 by Shanghai De Novo Pharmatech for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval

DN-1508052 is under clinical development by Shanghai De Novo Pharmatech and currently in Phase I for Transitional Cell Cancer (Urothelial...

Likelihood of Approval and Phase Transition Success Rate Model - DN-1508052 in Transitional Cell Cancer (Urothelial Cell Cancer)

Data Insights

DN-1508052 by Shanghai De Novo Pharmatech for Penile Cancer: Likelihood of Approval

DN-1508052 is under clinical development by Shanghai De Novo Pharmatech and currently in Phase I for Penile Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - DN-1508052 in Penile Cancer

Data Insights

DN-1508052 by Shanghai De Novo Pharmatech for Anal Cancer: Likelihood of Approval

DN-1508052 is under clinical development by Shanghai De Novo Pharmatech and currently in Phase I for Anal Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - DN-1508052 in Anal Cancer

Data Insights

DN-1508052 by Shanghai De Novo Pharmatech for Sarcomas: Likelihood of Approval

DN-1508052 is under clinical development by Shanghai De Novo Pharmatech and currently in Phase I for Sarcomas. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - DN-1508052 in Sarcomas

Data Insights

DN-1508052 by Shanghai De Novo Pharmatech for Hepatocellular Carcinoma: Likelihood of Approval

DN-1508052 is under clinical development by Shanghai De Novo Pharmatech and currently in Phase I for Hepatocellular Carcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - DN-1508052 in Hepatocellular Carcinoma

Data Insights

DN-1508052 by Shanghai De Novo Pharmatech for Bladder Cancer: Likelihood of Approval

DN-1508052 is under clinical development by Shanghai De Novo Pharmatech and currently in Phase I for Bladder Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - DN-1508052 in Bladder Cancer

Data Insights

DN-1508052 by Shanghai De Novo Pharmatech for Melanoma: Likelihood of Approval

DN-1508052 is under clinical development by Shanghai De Novo Pharmatech and currently in Phase I for Melanoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - DN-1508052 in Melanoma

Data Insights

DN-1508052 by Shanghai De Novo Pharmatech for Colorectal Cancer: Likelihood of Approval

DN-1508052 is under clinical development by Shanghai De Novo Pharmatech and currently in Phase I for Colorectal Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - DN-1508052 in Colorectal Cancer

Data Insights

DN-1508052 by Shanghai De Novo Pharmatech for Prostate Cancer: Likelihood of Approval

DN-1508052 is under clinical development by Shanghai De Novo Pharmatech and currently in Phase I for Prostate Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - DN-1508052 in Prostate Cancer